Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. - Wikidata - wikimedia - TriplyDB

Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.

Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.

http://www.wikidata.org/entity/Q44763401

about

Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults Duloxetine in the treatment of stress urinary incontinence Coadministration of low-dose serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine with α 2-adrenoceptor blockers to treat both female and male mild-to-moderate stress urinary incontinence (SUI)Duloxetine compared with placebo for treating women with symptoms of overactive bladder.Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial Stress incontinence.Neural control of the lower urinary tract: peripheral and spinal mechanisms Neural control of the female urethral and anal rhabdosphincters and pelvic floor muscles.The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis.Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports.Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence Duloxetine in the treatment of major psychiatric and neuropathic disorders.Evaluation of efficacy of duloxetine in stress urinary incontinence in women.Current management of stress urinary incontinence.Duloxetine: a new approach for treating stress urinary incontinence.Safety and adverse event profile of duloxetine.Pharmacological management of women with mixed urinary incontinence.Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice.An overview of stress urinary incontinence treatment in women.The treatment of urinary incontinence with Duloxetine.Update on duloxetine for the management of stress urinary incontinence.The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.Duloxetine Treatment of Stress Urinary Incontinence in Women Does Not Induce Mania or Hypomania.Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study.Pharmacological treatment of pure stress urinary incontinence: a narrative review.Assessment of overactive bladder in women antidepressant users.Properties of urethral rhabdosphincter motoneurons and their regulation by noradrenaline.Duloxetine in the treatment of stress urinary incontinence.Duloxetine: an innovative approach for treating stress urinary incontinence.[Medical therapy of urinary incontinence].Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence?Reductions in stress urinary incontinence episodes: what is clinically important for women?Nocturia, depression and antidepressant medication.Polymeric Microspheres for Medical Applications.The effect of duloxetine on urethral sphincter morphology.75NC007 device for noninvasive stress urinary incontinence management in women: a randomized controlled trial.Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test.Role of the serotonergic system in urethral continence reflexes during sneezing in rats.Treatment of stress urinary incontinence using a copolymer system: impact on quality of life.

P2860

Q24246568-1C559653-75A6-4298-A531-46D169163E59 Q24680252-A1B4F16A-FCC7-482C-B57E-41AC4D435554 Q26860846-8E2DD219-6EE8-48EA-8D5F-3DE553CFB207 Q30443662-2ACE9BBF-AEF6-459D-BA24-A3CD7FAA49AD Q33316575-54BB635D-FAFF-4215-AD69-D8CE6A44AA3B Q34010677-2A24F775-24AE-4E02-9733-A9003FD171E7 Q34020395-6F9CFCD7-8002-4A91-9305-570240927602 Q34085595-31DA8D76-9BA4-4E27-ACD9-AE153ADE4229 Q34333544-920175B0-21A7-46A6-92EC-A17E2BFB6405 Q34552333-C1ECFD1B-AB70-4F5A-B295-3ABF754B85EF Q34769139-14CBEA1D-001C-41FC-A849-5F3532CCFF63 Q34770302-B9C5F654-46A7-4053-931A-79EBC1ABCB42 Q34844161-B54D376C-CC28-4678-B5AA-EE973F69FAF5 Q35771615-D59E38DF-5EC2-4C31-BA52-2F333D22D506 Q35859638-0661E75D-6172-4B92-95E3-B15FCDFD60B5 Q36299961-A36F5C51-F277-4951-8ED6-0884B59DF07F Q36451416-45077834-44F0-4EAD-9517-1EDF2BEB0B0A Q36729973-1BBAC9B4-2532-45BD-9D97-327C474BAB95 Q36921864-6AA76187-F4C7-4508-9D84-8DCF92D693B1 Q37130272-9CD5E1E6-4B19-4573-95ED-547C86B5724A Q37199879-817A3D39-D4C5-4F30-9916-B11ED68D6780 Q37360532-27491A91-1ACC-46BD-BE29-20C7A8263E4B Q37708622-22BD3078-E7B9-43FE-AE7D-9C5724D4C81B Q37737694-C51038C4-2231-437E-9E7E-62E63303EC16 Q38335674-9293FABF-E568-48B3-A3E6-31763FC27EF1 Q40656507-E9C9CAAD-EF18-4268-8CF8-FEE36502D832 Q42848230-F8E1E285-A0EF-4E55-A39A-A88D3075064A Q43267071-C4F22DE2-E171-401B-BEBE-C0F28F96DE9A Q44893712-1AB833C1-1E17-4C15-BBC4-945347D08849 Q45194161-61858CEA-0A39-470E-B967-04B96F102108 Q45902947-B3BD479E-4AB8-4B07-B870-B52166DD7161 Q45993198-2539401A-B933-4E5C-A584-E74D4B6140F0 Q46407827-D12A378B-198D-4801-96AC-9ACD79A00C37 Q46716924-CF358743-835E-43C6-8A5D-9110C379C794 Q46769060-57FF9ADF-F1CE-4852-9DEB-328C1A735C1A Q46801499-62E6A4F5-587C-4D58-AE9D-830C28BCF87B Q46864021-CB4D4EBE-58B8-4B12-90BD-29319BC3CD31 Q50014986-319D82D5-96F0-4026-BE04-D8345168E535 Q51582363-7103ACBF-634D-4BDE-8EC8-354DA3509FEC

P2860

Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.

http://www.wikidata.org/entity/Q44763401

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@en

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@nl

type

label

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@en

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@nl

prefLabel

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@en

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@nl

P1433

Q44763401-66F477AE-9A41-4D78-9722-FA6694A50C06

P1476

Q44763401-55D7BC5F-7937-4C4E-A6B5-F997D0671FF2

P2093

Q44763401-01242A51-D3B6-4700-BD1A-69A0356A5015

Q44763401-170819C2-0FA9-4216-A58A-DB7ABF1324E3

Q44763401-200DD03B-399F-4091-9FED-C45C30B5B9B5

Q44763401-6AA1A09C-982D-409C-BEC0-E7DCCB9FC2BA

Q44763401-85E534A0-DE88-4D53-B110-0ED0A0F0213D

Q44763401-91AD20E6-DF3F-4B70-98B0-C428C33EDCFF

Q44763401-DC06450C-68A3-4B4C-904E-77FB803CA853

P2860

Q44763401-0649A606-DD3A-4C12-A795-A87DDE62EAEF

Q44763401-151896C8-4542-44B3-AEE5-E89792A71B3D

Q44763401-43387891-6862-45FE-9202-D3EB991EC0C9

Q44763401-4696C860-6706-4E6F-BF04-C4AA8FEB3E2E

Q44763401-4C17BC0D-541C-4C44-85F6-729C1AD09F01

Q44763401-5F7E6B2A-60D5-483F-9D4D-D55509F6873D

Q44763401-C428AB45-0871-4AFD-9468-F3990F7F5D67

Q44763401-D852B749-A448-4E93-932F-8A985F6FAF09

Q44763401-F7503D4D-1838-4891-A0F1-E93208DEA3F6

Q44763401-FCF734DD-75A8-485C-9087-6C5513F1768D

P304

Q44763401-C96C636D-BA43-4921-A99A-C71A8419AAD9

P31

Q44763401-F5EB58EB-C18A-4F49-94F6-75AECFB09A47

P356

Q44763401-49E67F82-B37A-43BD-BC30-347CEF040AFA

P433

Q44763401-F3FF612D-33E7-465E-AA59-ACB767E9B7E9

P478

Q44763401-2665065E-D5B9-48F0-BC4F-98C833D2E815

P50

Q44763401-FCC0C2CE-2D99-4215-8312-8AE1F3ED9642

P577

Q44763401-E3F7B68B-D16D-48C4-BC99-B8791166F0C8

P5875

Q44763401-066F852D-46E9-4652-8F16-3C2ECC7FEF1E

P698

Q44763401-DF956C6F-324A-4DED-82E5-3952F47A3746

P921

Q44763401-28537BF5-9830-4431-94DD-5B55804B3A3D

P356

J.1471-0528.2004.00067.X

P1433

BJOG: an International Journal of Obstetrics and Gynaecology

P1476

Duloxetine versus placebo in t ...... h stress urinary incontinence.

@en

P2093

Duloxetine Urinary Incontinence Study Group

http://www.w3.org/2001/XMLSchema#string

Ilker Yalcin

http://www.w3.org/2001/XMLSchema#string

Mark Slack

http://www.w3.org/2001/XMLSchema#string

Paul Abrams

http://www.w3.org/2001/XMLSchema#string

Philip van Kerrebroeck

http://www.w3.org/2001/XMLSchema#string

Rainer Lange

http://www.w3.org/2001/XMLSchema#string

Richard C Bump

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat.

Alpha 2-adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat.

Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.

Duloxetine versus placebo in the treatment of stress urinary incontinence.

Validation of two global impression questionnaires for incontinence.

Pelvic organ prolapse surgery in the United States, 1997.

Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats.

Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N-dimethyltryptamine.

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

P304

249-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1471-0528.2004.00067.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Jacques Wyndaele

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8694023

http://www.w3.org/2001/XMLSchema#string

P698

14961887

http://www.w3.org/2001/XMLSchema#string

P921